Visual Abstract

Background: Management of chronic kidney disease (CKD) patients includes efforts directed toward modifying traditional cardiovascular risk factors. Such efforts include optimal management of hypertension together with the initiation of statin therapy. Methods: In this observational study, we determine the modifying effect of statins on the relationship of systolic blood pressure (SBP) goal with mortality and other outcomes in patients with CKD participating in a clinical trial. At baseline, 2,646 CKD patients (estimated glomerular filtration rate < 60 mL/min/1.73 m2) were randomized to an intensive SBP goal < 120 mm Hg or standard SBP goal <140 mm Hg. One thousand two hundred and seventy-three were not on statin, 1,354 were on a statin, and in 19 the use of statin was unknown. The 2 primary outcomes were all-cause mortality and cardiovascular disease (CVD) mortality. Results: The relationships of SBP goal with all-cause mortality (interaction p = 0.009) and cardiovascular (CV) mortality (interaction p = 0.021) were modified by the use of statin after adjusting for age, gender, race, CVD history, smoking, aspirin use, and blood pressure at baseline. In the statin group, targeting SBP to < 120 mm Hg compared to SBP < 140 mm Hg significantly reduced the risk of all-cause mortality (adjusted hazard ratio [aHR] 0.44 [0.28–0.71]; event rates 1.16 vs. 2.5 per 100 patient-years) and CV mortality (aHR 0.29 [0.12–0.74]; event rates 0.28 vs. 0.92 per 100 patient-years) after a median follow-up of 3.26 years. In the non-statin group, the risk of all-cause mortality (aHR 1.07 [0.69–1.66]; event rates 2.01 vs. 1.94 per 100 patient-years) and CV mortality (aHR 1.42 [0.56–3.59]; event rates 0.52 vs. 0.41 per 100 patient-years) were not significantly different in both SBP goal arms. Conclusion: The combination of statin therapy and intensive SBP management leads to improved survival in hypertensive patients with CKD.

1.
Anderson AH, Yang W, Townsend RR, Pan Q, Chertow GM, Kusek JW, et al.; Chronic Renal Insufficiency Cohort Study Investigators. Time-updated systolic blood pressure and the progression of chronic kidney disease: a cohort study.
Ann Intern Med
. 2015 Feb; 162(4): 258–65.
2.
Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization.
N Engl J Med
. 2004 Sep; 351(13): 1296–305.
3.
Muntner P, Anderson A, Charleston J, Chen Z, Ford V, Makos G, et al.; Chronic Renal Insufficiency Cohort (CRIC) Study Investigators. Hypertension awareness, treatment, and control in adults with CKD: results from the Chronic Renal Insufficiency Cohort (CRIC) Study.
Am J Kidney Dis
. 2010 Mar; 55(3): 441–51.
4.
Wright JT Jr, Williamson JD, Whelton PK, Snyder JK, Sink KM, Rocco MV, et al.; SPRINT Research Group. A Randomized Trial of Intensive versus Standard Blood-Pressure Control.
N Engl J Med
. 2015 Nov; 373(22): 2103–16.
5.
Cheung AK, Rahman M, Reboussin DM, Craven TE, Greene T, Kimmel PL, et al.; SPRINT Research Group. Effects of Intensive BP Control in CKD.
J Am Soc Nephrol
. 2017 Sep; 28(9): 2812–23.
6.
National Guideline C. KDIGO clinical practice guideline for the management of blood pressure in chronic kidney disease. 2012.
7.
Baigent C, Landray MJ, Reith C, Emberson J, Wheeler DC, Tomson C, et al.; SHARP Investigators. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial.
Lancet
. 2011 Jun; 377(9784): 2181–92.
8.
Palmer SC, Navaneethan SD, Craig JC, Johnson DW, Perkovic V, Hegbrant J, et al.
HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis. Cochrane Database of Systematic Reviews
. John Wiley & Sons, Ltd; 2014.
9.
Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D; Modification of Diet in Renal Disease Study Group. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation.
Ann Intern Med
. 1999 Mar; 130(6): 461–70.
10.
Rosenbaum PR, Rubin DB. The central role of the propensity score in observational studies for causal effects.
Biometrika
. 1983; 70(1): 41–55.
11.
Fitzmaurice G. Confounding: regression adjustment.
Nutrition
. 2006 May; 22(5): 581–3.
12.
Bowry SK, Schoder V, Apel C. An inadvertent but explicable error in calculating number needed to treat for reporting survival data.
J Am Soc Nephrol
. 2014 May; 25(5): 875–6.
13.
Lash JP, Go AS, Appel LJ, He J, Ojo A, Rahman M, et al.; Chronic Renal Insufficiency Cohort (CRIC) Study Group. Chronic Renal Insufficiency Cohort (CRIC) Study: baseline characteristics and associations with kidney function.
Clin J Am Soc Nephrol
. 2009 Aug; 4(8): 1302–11.
14.
Lewington S, Clarke R, Qizilbash N, Peto R, Collins R; Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies.
Lancet
. 2002 Dec; 360(9349): 1903–13.
15.
Navaneethan SD, Schold JD, Jolly SE, Arrigain S, Blum MF, Winkelmayer WC, et al. Blood pressure parameters are associated with all-cause and cause-specific mortality in chronic kidney disease.
Kidney Int
. 2017 Nov; 92(5): 1272–81.
16.
Whelton PK, Carey RM, Aronow WS, Casey DE Jr, Collins KJ, Dennison Himmelfarb C, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.
Hypertension
. 2018 Jun; 71(6): 1269–324.
17.
Wanner C, Tonelli M; Kidney Disease: Improving Global Outcomes Lipid Guideline Development Work Group Members. KDIGO Clinical Practice Guideline for Lipid Management in CKD: summary of recommendation statements and clinical approach to the patient.
Kidney Int
. 2014 Jun; 85(6): 1303–9.
18.
Strazzullo P, Kerry SM, Barbato A, Versiero M, D’Elia L, Cappuccio FP. Do statins reduce blood pressure?: a meta-analysis of randomized, controlled trials.
Hypertension
. 2007 Apr; 49(4): 792–8.
19.
Ge CJ, Lu SZ, Chen YD, Wu XF, Hu SJ, Ji Y. Synergistic effect of amlodipine and atorvastatin on blood pressure, left ventricular remodeling, and C-reactive protein in hypertensive patients with primary hypercholesterolemia.
Heart Vessels
. 2008 Mar; 23(2): 91–5.
20.
Ferrier KE, Muhlmann MH, Baguet JP, Cameron JD, Jennings GL, Dart AM, et al. Intensive cholesterol reduction lowers blood pressure and large artery stiffness in isolated systolic hypertension.
J Am Coll Cardiol
. 2002 Mar; 39(6): 1020–5.
21.
Kamberi LS, Bedri Bakalli A, Muhamet Budima N, Rashit Gorani D, Karabulut AM, Talat Pallaska K. Pleiotropic and Lipid-lowering Effects of Statins in Hypertension.
Mater Sociomed
. 2012; 24(2): 84–6.
22.
Drapala A, Sikora M, Ufnal M. Statins, the renin-angiotensin-aldosterone system and hypertension - a tale of another beneficial effect of statins.
J Renin Angiotensin Aldosterone Syst
. 2014 Sep; 15(3): 250–8.
23.
Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol.
Circulation
. 2018 Nov:CIR0000000000000625.
24.
Shepherd J, Kastelein JJ, Bittner V, Deedwania P, Breazna A, Dobson S, et al.; TNT (Treating to New Targets) Investigators. Intensive lipid lowering with atorvastatin in patients with coronary heart disease and chronic kidney disease: the TNT (Treating to New Targets) study.
J Am Coll Cardiol
. 2008 Apr; 51(15): 1448–54.
25.
Tonelli M, Wanner C; Kidney Disease: Improving Global Outcomes Lipid Guideline Development Work Group Members. Lipid management in chronic kidney disease: synopsis of the Kidney Disease: Improving Global Outcomes 2013 clinical practice guideline.
Ann Intern Med
. 2014 Feb; 160(3): 182.
26.
Rocco MV, Sink KM, Lovato LC, Wolfgram DF, Wiegmann TB, Wall BM, et al.; SPRINT Research Group. Effects of Intensive Blood Pressure Treatment on Acute Kidney Injury Events in the Systolic Blood Pressure Intervention Trial (SPRINT).
Am J Kidney Dis
. 2018 Mar; 71(3): 352–61.
27.
Saran R, Robinson B, Abbott KC, Agodoa LY, Bhave N, Bragg-Gresham J, et al. US Renal Data System 2017 Annual Data Report: Epidemiology of Kidney Disease in the United States.
Am J Kidney Dis
. 2018 Mar; 71(3S1 Suppl 1):A7–8.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.